Inimmune

inimmune is a biotechnology company developing immune therapies and components for more effective vaccines.

Inimmune is focused on developing the next generation of next generation vaccines and immunotherapeutics.

Inimmune was started in 2016 by co-founders Drs. Kendal Ryter, Helene Bazin-Lee, David Burkhart and Jay Evans, along with a team of 11 experienced scientists from GlaxoSmithKline. The company is headquartered in Missoula, Montana.

 

Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity and cancer.

 

Inimmune is nationally recognized for its innovative approach to treatments leveraging the immune system, especially its development of novel adjuvants, which are compounds added to therapies to improve or direct an immune response.

 

Inimmune is backed by Two Bear Capital. The company raised $22M in Series A round on July 08, 2020. This brings Inimmune's total funding to $22.6M to date.

 

 

  • Year founded: 2016
  • Funding Info: $22.6M over 2 Rounds (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Missoula
  • State: Montana
  • Country: United States
Related businesses